-
1
-
-
14944385553
-
Global cancer statistics in the year 2002
-
Parkin DM, Bray F, Ferlay J, et al. (2005) Global cancer statistics in the year 2002. CA Cancer J Clin 55:74-108
-
(2005)
CA Cancer J Clin
, vol.55
, pp. 74-108
-
-
Parkin, D.M.1
Bray, F.2
Ferlay, J.3
-
2
-
-
0024454042
-
Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer
-
Preusser P, Wilke H, Achterrath W, et al. (1989) Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7:1310-1317
-
(1989)
J Clin Oncol
, vol.7
, pp. 1310-1317
-
-
Preusser, P.1
Wilke, H.2
Achterrath, W.3
-
3
-
-
0028032976
-
Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: A prospective randomized trial of the Italian oncology group for clinical research
-
Cocconi G, Bella M, Zironi S, et al. (1994) Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian oncology group for clinical research. J Clin Oncol 12:2687-2693
-
(1994)
J Clin Oncol
, vol.12
, pp. 2687-2693
-
-
Cocconi, G.1
Bella, M.2
Zironi, S.3
-
4
-
-
0018931354
-
5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer
-
Macdonald JS, Schein PS, Wooley PV, et al. (1980) 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 93:533-536
-
(1980)
Ann Intern Med
, vol.93
, pp. 533-536
-
-
MacDonald, J.S.1
Schein, P.S.2
Wooley, P.V.3
-
6
-
-
0028016155
-
A phase II study in advanced gastroesophageal cancer using epirubicin and cisplatin in combination with infusion 5-fluorouracil (ECF)
-
Findlay M, Cunningham D, Norman A, et al. (1994) A phase II study in advanced gastroesophageal cancer using epirubicin and cisplatin in combination with infusion 5-fluorouracil (ECF). Ann Oncol 5:609-616
-
(1994)
Ann Oncol
, vol.5
, pp. 609-616
-
-
Findlay, M.1
Cunningham, D.2
Norman, A.3
-
8
-
-
0023726563
-
Report on national wide pooled data and cohort investigation in UFT Phase II study
-
Oka K, Taguchi T, Kimura K (1988) Report on national wide pooled data and cohort investigation in UFT Phase II study. Cancer Chemother Pharmacol 22:333-338
-
(1988)
Cancer Chemother Pharmacol
, vol.22
, pp. 333-338
-
-
Oka, K.1
Taguchi, T.2
Kimura, K.3
-
9
-
-
9344248389
-
Antitumor activity of 1M tegafur-0.4 M 5-chloro-2,4-dihydroxypyrimidine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats
-
Shirasaka T, Nakano K, Takechi T, et al. (1996) Antitumor activity of 1M tegafur-0.4 M 5-chloro-2,4-dihydroxypyrimidine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56:2602-2606
-
(1996)
Cancer Res
, vol.56
, pp. 2602-2606
-
-
Shirasaka, T.1
Nakano, K.2
Takechi, T.3
-
10
-
-
11544323426
-
Preclinical antitumor efficacy of S-1; A new oral formulation of 5-fluorouracil on human tumor xenografts
-
Fukushima M, Satake H, Uchida J, et al. (1998) Preclinical antitumor efficacy of S-1; a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol 13:693-698
-
(1998)
Int J Oncol
, vol.13
, pp. 693-698
-
-
Fukushima, M.1
Satake, H.2
Uchida, J.3
-
11
-
-
0032819756
-
The S-1 gastrointestinal cancer study group: An early phase II study of oral S-1, a newly developed 5-fluoruracil derivative for advanced and recurrent gastrointestinal cancers
-
Sugimachi K, Maehara Y, Horikoshi N, et al. (1999) The S-1 gastrointestinal cancer study group: an early phase II study of oral S-1, a newly developed 5-fluoruracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 57:202-210
-
(1999)
Oncology
, vol.57
, pp. 202-210
-
-
Sugimachi, K.1
Maehara, Y.2
Horikoshi, N.3
-
12
-
-
0032189218
-
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M Gimestat-1 M otastat potassium) in advanced gastric cancer patients
-
Sakata Y, Ohtsu A, Horikoshi N, et al. (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M Gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715-1720
-
(1998)
Eur J Cancer
, vol.34
, pp. 1715-1720
-
-
Sakata, Y.1
Ohtsu, A.2
Horikoshi, N.3
-
13
-
-
6544263262
-
Pharmakokinetic study of S-1, a novel oral fluorouracil antitumor drug
-
Hirata K, Horikoshi N, Aiba K, et al. (1999) Pharmakokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5:2000-2005
-
(1999)
Clin Cancer Res
, vol.5
, pp. 2000-2005
-
-
Hirata, K.1
Horikoshi, N.2
Aiba, K.3
-
14
-
-
0034029776
-
The S-1 gastrointestinal cancer study group: Phase II study of S-1, a novel derivative 5-fluorouracil, in advanced gastric cancer
-
Koizumi W, Kurihara M, Nakano S, Hasegawa K (2000) The S-1 gastrointestinal cancer study group: Phase II study of S-1, a novel derivative 5-fluorouracil, in advanced gastric cancer. Oncology 58:191-197
-
(2000)
Oncology
, vol.58
, pp. 191-197
-
-
Koizumi, W.1
Kurihara, M.2
Nakano, S.3
Hasegawa, K.4
-
15
-
-
0037570623
-
S-1 in gastric cancer: A comprehensive review
-
suppl1
-
Maehara Y (2003) S-1 in gastric cancer: a comprehensive review. Gastric Cancer 6(suppl 1):2-8
-
(2003)
Gastric Cancer
, vol.6
, pp. 2-8
-
-
Maehara, Y.1
-
16
-
-
0035033019
-
Pharmacogenomics: Unlocking the human genome for better drug therapy
-
McLeod HL, Evans WE (2001) Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 41:101-121
-
(2001)
Annu Rev Pharmacol Toxicol
, vol.41
, pp. 101-121
-
-
McLeod, H.L.1
Evans, W.E.2
-
17
-
-
0033569516
-
Pharmacogenomics: Translating functional genomics into rational therapeutics
-
Evans WE, Relling M (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491
-
(1999)
Science
, vol.286
, pp. 487-491
-
-
Evans, W.E.1
Relling, M.2
-
18
-
-
0029620911
-
Potential of the histoculture drug-response assay to contribute to cancer patient survival
-
Kubota T, Sasano N, Abe O, et al., and the Chemosensitivity study group for the Histoculture drug-response assay (1995) Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res 1:1537-1543
-
(1995)
Clin Cancer Res
, vol.1
, pp. 1537-1543
-
-
Kubota, T.1
Sasano, N.2
Abe, O.3
-
19
-
-
0032837081
-
Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves
-
Nishiyama M, Yamamoto W, Park JS, et al. (1999) Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 5:2620-2628
-
(1999)
Clin Cancer Res
, vol.5
, pp. 2620-2628
-
-
Nishiyama, M.1
Yamamoto, W.2
Park, J.S.3
-
20
-
-
0033090335
-
Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression level can predict 5-fluorouracil resistance in human gastrointestinal cancer cells
-
Kirihara Y, Yamamoto W, Toge T, Nishiyama M (1999) Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression level can predict 5-fluorouracil resistance in human gastrointestinal cancer cells. Int J Oncol 14:551-556
-
(1999)
Int J Oncol
, vol.14
, pp. 551-556
-
-
Kirihara, Y.1
Yamamoto, W.2
Toge, T.3
Nishiyama, M.4
-
21
-
-
0030787605
-
Molecular targeting of mitomycin C chemotherapy
-
Nishiyama M, Suzuki K, Kumazaki T, et al. (1997) Molecular targeting of mitomycin C chemotherapy. Int J Cancer 72:649-656
-
(1997)
Int J Cancer
, vol.72
, pp. 649-656
-
-
Nishiyama, M.1
Suzuki, K.2
Kumazaki, T.3
-
22
-
-
0033038390
-
Regulatory network of mitomycin C action in human colon cancer cells
-
Suzuki K, Yamamoto W, Park JS, et al. (1999) Regulatory network of mitomycin C action in human colon cancer cells. Jpn J Cancer Res 90:571-577
-
(1999)
Jpn J Cancer Res
, vol.90
, pp. 571-577
-
-
Suzuki, K.1
Yamamoto, W.2
Park, J.S.3
-
23
-
-
0036160987
-
6-Methylguanine DNA methytransferase (MGMT) as a determinant of resistance to camptothecin derivatives
-
6-Methylguanine DNA methytransferase (MGMT) as a determinant of resistance to camptothecin derivatives. Jpn J Cancer Res 93:93-102
-
(2002)
Jpn J Cancer Res
, vol.93
, pp. 93-102
-
-
Okamoto, R.1
Takano, H.2
Okamura, T.3
-
24
-
-
0035512241
-
Unique action determinants of double acting topoisomerase inhibitor, TAS-103
-
Okamoto R, Takano H, Sekikawa T, et al. (2001) Unique action determinants of double acting topoisomerase inhibitor, TAS-103. Int J Oncol 19:921-927
-
(2001)
Int J Oncol
, vol.19
, pp. 921-927
-
-
Okamoto, R.1
Takano, H.2
Sekikawa, T.3
-
25
-
-
0034941111
-
Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells
-
Yamamoto W, Verweij J, de Bruijn P, et al. (2001) Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells. Anti-Cancer Drug 12:419-432
-
(2001)
Anti-Cancer Drug
, vol.12
, pp. 419-432
-
-
Yamamoto, W.1
Verweij, J.2
De Bruijn, P.3
-
26
-
-
0030739278
-
Overcoming CPT-11 resistance by using a biococlaurine alkaloid, cepharanthine, to modulate plasma trans-membrane potential
-
Aogi K, Nishiyama M, Kim R, et al. (1997) Overcoming CPT-11 resistance by using a biococlaurine alkaloid, cepharanthine, to modulate plasma trans-membrane potential. Int J Cancer 72:295-300
-
(1997)
Int J Cancer
, vol.72
, pp. 295-300
-
-
Aogi, K.1
Nishiyama, M.2
Kim, R.3
-
27
-
-
17644445630
-
Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers
-
Park JS, Yamamoto W, Sekikawa T, et al. (2002) Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers. Int J Oncol 20:333-338
-
(2002)
Int J Oncol
, vol.20
, pp. 333-338
-
-
Park, J.S.1
Yamamoto, W.2
Sekikawa, T.3
-
28
-
-
0842330394
-
Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer
-
Koizumi W, Tanabe S, Saigenji K, et al. (2003) Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89:2207-2212
-
(2003)
Br J Cancer
, vol.89
, pp. 2207-2212
-
-
Koizumi, W.1
Tanabe, S.2
Saigenji, K.3
-
29
-
-
18544367472
-
Current status and future prospects of chemotherapy for metastatic gastric cancer: A review
-
Ohtsu A (2005) Current status and future prospects of chemotherapy for metastatic gastric cancer: a review. Gastric Cancer 8:95-102
-
(2005)
Gastric Cancer
, vol.8
, pp. 95-102
-
-
Ohtsu, A.1
-
30
-
-
18544378559
-
Recent advances in multimodal treatment for gastric cancer: A review
-
Lordick F, Siewert JR (2005) Recent advances in multimodal treatment for gastric cancer: a review. Gastric Cancer 8:78-85
-
(2005)
Gastric Cancer
, vol.8
, pp. 78-85
-
-
Lordick, F.1
Siewert, J.R.2
-
31
-
-
0034811794
-
Recent advances in the treatment of gastric cancer
-
Sun W, Haller DG (2001) Recent advances in the treatment of gastric cancer. Drugs 61:1545-1551
-
(2001)
Drugs
, vol.61
, pp. 1545-1551
-
-
Sun, W.1
Haller, D.G.2
-
32
-
-
21644445993
-
Final results of a randomized controlled phase III trial (TAX325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC)
-
(abstract 4002). (accessed August 9, 2005)
-
Moiseyenko VM, Ajani A, Tjulandin SA, et al. (2005) Final results of a randomized controlled phase III trial (TAX325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). Proc Am Soc Clin Oncol 23:308s (abstract 4002). http://www.asco.org/ac/1,1003,_12-002511-00_18-0034-00_19- 004244,00.asp (accessed August 9, 2005)
-
(2005)
Proc Am Soc Clin Oncol
, vol.23
-
-
Moiseyenko, V.M.1
Ajani, A.2
Tjulandin, S.A.3
-
33
-
-
20044393181
-
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: A randomized phase II study
-
Thuss-Patience PC, Kretzschmar A, Repp M, et al. (2005) Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol 23:494-501
-
(2005)
J Clin Oncol
, vol.23
, pp. 494-501
-
-
Thuss-Patience, P.C.1
Kretzschmar, A.2
Repp, M.3
-
34
-
-
20244364251
-
Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer
-
Chun JH, Kim HK, Lee JS, et al. (2005) Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 28:188-194
-
(2005)
Am J Clin Oncol
, vol.28
, pp. 188-194
-
-
Chun, J.H.1
Kim, H.K.2
Lee, J.S.3
-
35
-
-
38049047178
-
Capecitabine and oxaliplatin for advanced esophagogastric cancer
-
Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom et al.
-
Cunningham D, Starling N, Rao S, et al.; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46
-
(2008)
N Engl J Med
, vol.358
, pp. 36-46
-
-
Cunningham, D.1
Starling, N.2
Rao, S.3
-
36
-
-
33750096084
-
Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results
-
Kang Y, Kang WK, Shin DB, et al. (2006) Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results. ASCO Meeting Abstracts June 20:4018
-
(2006)
ASCO Meeting Abstracts June
, vol.20
, pp. 4018
-
-
Kang, Y.1
Kang, W.K.2
Shin, D.B.3
-
37
-
-
35748972266
-
Randomized phase III study of 5-fluorouracil (5-FU) alone versuscombination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912)
-
18S
-
Boku N, Yamamoto S, Shirao K, et al. (2007) Randomized phase III study of 5-fluorouracil (5-FU) alone versuscombination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). Clin Oncol 25(18S):LBA4513
-
(2007)
Clin Oncol
, vol.25
, pp. 4513
-
-
Boku, N.1
Yamamoto, S.2
Shirao, K.3
-
38
-
-
40749153540
-
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial
-
Koizumi W, Narahara H, Hara T, et al. (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215-221
-
(2008)
Lancet Oncol
, vol.9
, pp. 215-221
-
-
Koizumi, W.1
Narahara, H.2
Hara, T.3
-
39
-
-
45749130769
-
Irinotecan plus S-1(IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer: Preliminary results of a randomized phase III study (GC0301/TOP002)
-
18S
-
Chin K, Ishii H, Imamura H, et al. (2007) Irinotecan plus S-1(IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer: preliminary results of a randomized phase III study (GC0301/TOP002). J Clin Oncol 25(18S):4525
-
(2007)
J Clin Oncol
, vol.25
, pp. 4525
-
-
Chin, K.1
Ishii, H.2
Imamura, H.3
-
40
-
-
0023187085
-
Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile
-
Heggie GD, Sommadossi JP, Gross DS, et al. (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203-2206
-
(1987)
Cancer Res
, vol.47
, pp. 2203-2206
-
-
Heggie, G.D.1
Sommadossi, J.P.2
Gross, D.S.3
-
41
-
-
0042062300
-
Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: A study of 88 surgical specimens
-
Yoshinare K, Kubota T, Watanabe M, et al. (2003) Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens. Cancer Sci 94:633-638
-
(2003)
Cancer Sci
, vol.94
, pp. 633-638
-
-
Yoshinare, K.1
Kubota, T.2
Watanabe, M.3
-
42
-
-
4344564478
-
Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray
-
Park Ji-S, Yoo SY, Kim J-M, et al. (2004) Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. Cancer Lett 214:19-33
-
(2004)
Cancer Lett
, vol.214
, pp. 19-33
-
-
Park, J.-S.1
Yoo, S.Y.2
Kim, J.-M.3
-
43
-
-
0034676235
-
Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells
-
Chung YM, Park S, Park JK, et al. (2000) Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells. Cancer Lett 159:95-101
-
(2000)
Cancer Lett
, vol.159
, pp. 95-101
-
-
Chung, Y.M.1
Park, S.2
Park, J.K.3
-
44
-
-
0037660429
-
Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma
-
Fujii R, Seshimo A, Kameoka S (2003) Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol 8:72-78
-
(2003)
Int J Clin Oncol
, vol.8
, pp. 72-78
-
-
Fujii, R.1
Seshimo, A.2
Kameoka, S.3
-
45
-
-
0242658929
-
Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer
-
Ichikawa W, Uetake H, Shirota Y, et al. (2003) Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 89:1486-1492
-
(2003)
Br J Cancer
, vol.89
, pp. 1486-1492
-
-
Ichikawa, W.1
Uetake, H.2
Shirota, Y.3
-
46
-
-
33748499794
-
Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1
-
Ichikawa W, Takahashi T, Suto K, et al. (2006) Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer 119:1927-1933
-
(2006)
Int J Cancer
, vol.119
, pp. 1927-1933
-
-
Ichikawa, W.1
Takahashi, T.2
Suto, K.3
-
47
-
-
33847342945
-
Overexpression of orotate phosphoribosyl transferase (OPRT) gene enhances the effect of 5-FU on gastric cancer cell lines
-
Taomoto J, Yoshida K, Wada Y, et al. (2006) Overexpression of orotate phosphoribosyl transferase (OPRT) gene enhances the effect of 5-FU on gastric cancer cell lines. Oncology 70:458-464
-
(2006)
Oncology
, vol.70
, pp. 458-464
-
-
Taomoto, J.1
Yoshida, K.2
Wada, Y.3
-
48
-
-
3242679932
-
Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer
-
Yoshida K, Hirabayashi N, Takiyama W, et al. (2004) Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. Anticancer Res 24:1843-1852
-
(2004)
Anticancer Res
, vol.24
, pp. 1843-1852
-
-
Yoshida, K.1
Hirabayashi, N.2
Takiyama, W.3
-
49
-
-
33745227360
-
Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer
-
Yoshida K, Ninomiya M, Takakura N, et al. (2006) Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12:3402-3407
-
(2006)
Clin Cancer Res
, vol.12
, pp. 3402-3407
-
-
Yoshida, K.1
Ninomiya, M.2
Takakura, N.3
-
50
-
-
33745955340
-
Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines
-
Wada Y, Yoshida K, Suzuki T, et al. (2006) Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer 119:783-791
-
(2006)
Int J Cancer
, vol.119
, pp. 783-791
-
-
Wada, Y.1
Yoshida, K.2
Suzuki, T.3
-
51
-
-
3242720345
-
Cetuximab monotherapy and cetuximab plus irinotecan in iritenocan-refractory metastatic colorectal cancer
-
Cunningham D, Humblet Y, Siena S, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in iritenocan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345
-
(2004)
N Engl J Med
, vol.351
, pp. 337-345
-
-
Cunningham, D.1
Humblet, Y.2
Siena, S.3
-
52
-
-
17644400134
-
Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer
-
Lee BL, Lee HS, Jung J, et al. (2005) Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer. Clin Cancer Res 11:2518-2525
-
(2005)
Clin Cancer Res
, vol.11
, pp. 2518-2525
-
-
Lee, B.L.1
Lee, H.S.2
Jung, J.3
-
53
-
-
33947099498
-
Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model
-
Sven AL, Andreas G, Gudrun E, et al. (2007) Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 120:1803-1810
-
(2007)
Int J Cancer
, vol.120
, pp. 1803-1810
-
-
Sven, A.L.1
Andreas, G.2
Gudrun, E.3
-
54
-
-
0037020044
-
Identification of TOR signaling complexes: More TORC for the cell growth engine
-
Abraham RT (2002) Identification of TOR signaling complexes: more TORC for the cell growth engine. Cell 111:9-12
-
(2002)
Cell
, vol.111
, pp. 9-12
-
-
Abraham, R.T.1
-
55
-
-
0035012605
-
HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1-alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression
-
Laughner E, Taghavi P, Chiles K, et al. (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1-alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995-4004
-
(2001)
Mol Cell Biol
, vol.21
, pp. 3995-4004
-
-
Laughner, E.1
Taghavi, P.2
Chiles, K.3
|